1	HOUSE BILL NO. 392			
2	INTRODUCED BY J. ETCHART, E. KERR-CARPENTER, K. ZOLNIKOV, T. MOORE, J. GILLETTE			
3				
4	A BILL FOR AN ACT ENTITLED: "AN ACT REVISING LAWS RELATED TO DIRECT-ENTRY MIDWIVES;			
5	EXPANDING THE ABILITY FOR DIRECT-ENTRY MIDWIVES TO OBTAIN AND ADMINISTER CERTAIN			
6	PRESCRIPTION DRUGS; REQUIRING CERTAIN EDUCATION PRIOR TO THE ABILITY FOR DIRECT-			
7	ENTRY MIDWIVES TO ADMINISTER DRUGS; REQUIRING DIRECT-ENTRY MIDWIVES TO ESTABLISH			
8	PROTOCOLS FOR DRUG ADMINISTRATION; PROVIDING RULEMAKING AUTHORITY; AND AMENDING			
9	SECTION 37-27-302, MCA <del>; AND PROVIDING AN IMMEDIATE EFFECTIVE DATE</del> ."			
10				
11	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:			
12				
13	Section 1. Section 37-27-302, MCA, is amended to read:			
14	"37-27-302. Administration of prescription drugs <u> when prohibited exceptions when allowed</u>			
15	protocols rulemaking. (1) A Except as provided in subsection (2), a licensed direct-entry midwife may not			
16	dispense or administer prescription drugs other than newborn vitamin K (oral or intramuscular preparations),			
17	pitocin (intramuscular) postpartum, xylocaine (subcutaneous), and, in accordance with administrative rules			
18	adopted by the department of public health and human services, prophylactic eye agents to newborn infants.			
19	These drugs may be administered only if prescribed by a physician.			
20	(2) A licensed direct-entry midwife who has successfully completed accredited courses in			
21	pharmacology and intravenous therapy approved by the board and has obtained a license endorsement from			
22	the board may, during the practice of midwifery, directly obtain and administer the following:			
23	(a) oxygen;			
24	(b) postpartum antihemorrhagic agents, including:			
25	(i) pitocin (intramuscular);			
26	(ii) methylergonovine;			
27	(iii) misoprostol;			
28	(iv) tranexamic acid; and			



Amendment - 1st Reading-white - Requested by: Jodee Etchart - (H) Human Services					
- 2023 68th Legislature 2023		Drafter: Erin Sullivan, 406-444-3594	HB0392.001.001		
1	<u>(v)</u>	other postpartum antihemorrhagic drugs allowed by board rule;			
2	<u>(c)</u>	(c) injectable local anesthetics for the repair of up to second-degree lacerations;			
3	<u>(d)</u>	antibiotics for group b streptococcus prophylaxis consistent with guidelines of the United States			
4	centers for disease control and prevention;				
5	<u>(e)</u>	epinephrine administered for anaphylactic shock;			
6	<u>(f)</u>	intravenous fluids for fluid replacement and administration of approved medications;			
7	<u>(g)</u>	rho(d) immune globulin to prevent maternal immune sensitization to certain fetal blood types;			
8	<u>(h)</u>	n) newborn vitamin K or phytonadione (oral or intramuscular preparations);			
9	<u>(i)</u>	(i) in accordance with administrative rules adopted by the department of public health and human			
10	services, prophylactic eye agents to newborn infants; and				
11					
12					
13	(3) A licensed direct-entry midwife who administers drugs under this section must establish writte				
14	protocol, including but not limited to:				
15	(a) procurement of prescription drugs, which must be procured from a wholesale drug distributor				
16	pharmacy supplier licensed by the board of pharmacy provided for in 2-15-1733;				
17	(b) storage, inventory control, and disposal of prescription drugs; and				
18	(c) use and care of prescription drugs.				
19	<u>(4)</u>	(4) The board may adopt rules to implement this section."			
20					
21	NEW S	SECTION. Section 2. Effective date. [This act] is effective on passage and a	<del>oproval.</del>		
22		- END -			

